OR WAIT null SECS
August 01, 2017
Successful development requires coordinating and aligning drug and device design, focusing on a complete drug delivery system that meets patients’ needs.
July 19, 2017
The new label-free method for quantifying intracellular bioavailability can be used to predict drug exposure to target cells and hence its efficacy.
July 18, 2017
Researchers have demonstrated how an investigational drug currently in testing works against Niemann-Pick type C1, which may lead to treatments for other similar disorders.
July 12, 2017
FDA advisory committee has recommended for approval Novartis CAR-T cell therapy CTL019 for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients.
May 15, 2017
Catalent has signed an agreement with Therachon to support preclinical and clinical development of TA-46, a novel protein being developed to treat achondroplasia.
May 08, 2017
Biomedical researcher shares insights from a career dedicated to advancing therapeutic innovations for unmet medical needs.
April 07, 2017
The companies will work to co-develop FIN-524, a live biotherapeutic product composed of cultured bacteria strains.
April 06, 2017
FDA is in the center of the debate over developing and pricing new cancer therapies.
March 30, 2017
The company received priority review for its investigational CAR-T therapy to treat leukemia.
March 29, 2017
The mAb is the first approved treatment that targets the progressive form of the disease.